ConductScience.org, home

Library / Genes

PIK3CD: phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta

1 protein, 50 patents, 50 drugs, 483 trials, 8,360 NIH grants and 19,008 papers.

Gene 7

Its symbol and name are HGNC's, unless HGNC and NCBI Gene contradict each other.

FieldValueSource
SymbolPIK3CDHGNC
Namephosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit deltaHGNC
NCBI Gene ID5293NCBI Gene
HGNC IDHGNC:8977HGNC
EnsemblENSG00000171608NCBI Gene
AliasesAPDS, IMD14, IMD14A, IMD14B, P110DELTA, PI3K, PI3Kdelta, ROCHIS, p110DNCBI Gene
Typeprotein-codingNCBI Gene

Proteins 1

Reviewed human proteins whose Swiss-Prot entry states the gene.

UniProt entryProteinLengthStructuresGene stated inSource
O00329Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform1,04420Ensembl, GeneID, HGNCUniProt

Patents 50

Patents whose sequence listing holds the protein exactly: the same sequence, by SHA-256, length and CRC-64. A sequence a patent lists is not always one it claims.

PublicationPublishedSEQ ID NOProteinSource
EP 4661970 A12025-12-1762175O00329Espacenet
EP 4650780 A22025-11-199905O00329Espacenet
EP 4641201 A22025-10-2910180O00329Espacenet
JP 2025532979 A2025-10-03300O00329Espacenet
EP 4593850 A22025-08-06300O00329Espacenet
JP 2025517969 A2025-06-1210180O00329Espacenet
JP 2025517970 A2025-06-129905O00329Espacenet
WO 2025101914 A12025-05-156O00329Espacenet
US 12295971 B22025-05-13300O00329Espacenet
JP 2024123008 A2024-09-107611O00329Espacenet

Drugs 50

Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.

DrugChEMBL IDMechanismActionSource
ACALISIBCHEMBL4303323PI3-kinase p110-delta subunit inhibitorINHIBITORChEMBL
AMG-319CHEMBL4303596PI3-kinase p110-delta subunit inhibitorINHIBITORChEMBL
APITOLISIBCHEMBL1922094PI3-kinase class I inhibitorINHIBITORChEMBL
AZD-6482CHEMBL2165191PI3-kinase class I inhibitorINHIBITORChEMBL
AZD-8186CHEMBL3408248PI3-kinase p110-delta subunit inhibitorINHIBITORChEMBL
BGT-226CHEMBL3545096PI3-kinase class I inhibitorINHIBITORChEMBL
BGT-226 FREE BASECHEMBL3218578PI3-kinase class I inhibitorINHIBITORChEMBL
BUPARLISIBCHEMBL2017974PI3-kinase class I inhibitorINHIBITORChEMBL
CAL-263CHEMBL3545247PI3-kinase p110-delta subunit inhibitorINHIBITORChEMBL
COPANLISIBCHEMBL3218576PI3-kinase p110-delta subunit inhibitorINHIBITORChEMBL

Trials 483

Trials of those drugs. A trial joins the gene only through a drug that acts on it.

TrialDrugPhaseResults first postedSource
NCT07447076PAXALISIBPHASE2ClinicalTrials.gov
NCT07391215PAXALISIBPHASE1/PHASE2ClinicalTrials.gov
NCT07293403DUVELISIBPHASE2ClinicalTrials.gov
NCT07287202PAXALISIBPHASE1/PHASE2ClinicalTrials.gov
NCT07139873IDELALISIBPHASE3ClinicalTrials.gov
NCT07001384DUVELISIBPHASE1ClinicalTrials.gov
NCT06897358LENIOLISIBPHASE2ClinicalTrials.gov
NCT06846671IDELALISIBPHASE3ClinicalTrials.gov
NCT06810778DUVELISIBPHASE1/PHASE2ClinicalTrials.gov
NCT06757634GEDATOLISIBPHASE3ClinicalTrials.gov

NIH grants 8360

NIH projects whose papers are about the gene, through NIH's grant-paper links.

ProjectTitleIts papers about the geneNewest fiscal yearSource
P30CA016672Cancer Center Support Grant1952,025NIH's project files
P30CA008748Cancer Center Support Grant1392,025NIH's project files
P30CA016058Cancer Center Support Grant392,025NIH's project files
P30CA076292Moffitt Cancer Center Support Grant282,025NIH's project files
P30CA006973Regional Oncology Research Center212,025NIH's project files
P30CA046934University of Colorado Cancer Center Support Grant202,025NIH's project files
UL1TR001863Yale Clinical and Translational Science Award192,025NIH's project files
ZIAHL002346Tumor microenvironment in CLL and MCL: pathogenesis, targets, and therapy192,025NIH's project files
P30CA016086Cancer Center Support Grant182,025NIH's project files
P30CA068485Cancer Center Support Grant182,025NIH's project files

Papers 19008

Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.

PMIDFound bySource
42812104PubTator, text miningPubMed
42805311PubTator, text miningPubMed
42799298PubTator, text miningPubMed
42792733PubTator, text miningPubMed
42771852PubTator, text miningPubMed
42740508PubTator, text miningPubMed
42729315PubTator, text miningPubMed
42726435PubTator, text miningPubMed
42715866PubTator, text miningPubMed
42661698PubTator, text miningPubMed

The same record as JSON

Release gene-search-2026-11-11-0.1.0

ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

ChEMBL, through Open Targets: CC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence

ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

EMBL-EBI's patent proteins: EMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use

GenBank's patent files: GenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/

HGNC: CC0: https://www.genenames.org/about/license/

NCBI Gene: None named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/

NIH's project files and grant-paper links: Public domain (NIH RePORTER)

Open Targets: CC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence

PubTator 3: Public domain

UniProt: CC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license